Hologic (HOLX) Stock Price
Hologic Price
Over the last 19 years Hologic grew revenue by 12.2% annually, reaching 4.10 B USD. Earnings per share have grown at 12.8% per year over the last 19 years. For Hologic, the net margin of 13.8% is down versus 33.2% a few years ago. The consensus 12-month price target for Hologic is 77.52 USD, about 2.0% above where the stock trades today. Of 23 analysts, 0 rate the stock a buy — an overall Hold consensus. The stock trades about 20% above its 52-week low.
Hologic stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Hologic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hologic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hologic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Hologic Price |
|---|---|
| 4/7/2026 | 76.01 USD |
| 4/6/2026 | 76.06 USD |
| 4/2/2026 | 75.65 USD |
| 4/1/2026 | 75.60 USD |
| 3/31/2026 | 75.59 USD |
| 3/30/2026 | 75.55 USD |
| 3/27/2026 | 75.67 USD |
| 3/26/2026 | 75.69 USD |
| 3/25/2026 | 75.52 USD |
| 3/24/2026 | 75.55 USD |
| 3/23/2026 | 75.64 USD |
| 3/20/2026 | 75.41 USD |
| 3/19/2026 | 75.33 USD |
| 3/18/2026 | 75.33 USD |
| 3/17/2026 | 75.05 USD |
| 3/16/2026 | 75.15 USD |
| 3/13/2026 | 75.18 USD |
| 3/12/2026 | 75.21 USD |
| 3/11/2026 | 75.37 USD |
| 3/10/2026 | 75.54 USD |
| 3/9/2026 | 75.59 USD |
| 3/6/2026 | 75.74 USD |
| 3/5/2026 | 75.75 USD |
| 3/4/2026 | 75.67 USD |
| 3/3/2026 | 75.46 USD |
| 3/2/2026 | 75.45 USD |
| 2/27/2026 | 75.36 USD |
| 2/26/2026 | 75.23 USD |
| 2/25/2026 | 75.34 USD |
| 2/24/2026 | 75.35 USD |
Hologic Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.53 | 2.71 | 2.83 | 3.06 | 3.22 | 3.37 | 3.78 | 5.63 | 4.86 | 4.03 | 4.03 | 4.10 | 4.24 | 4.46 | 4.60 | 4.90 |
| 1.52 | 6.92 | 4.70 | 7.98 | 5.20 | 4.66 | 12.15 | 49.15 | -13.67 | -17.11 | – | 1.74 | 3.29 | 5.29 | 3.09 | 6.66 |
| 49.21 | 52.94 | 55.19 | 53.01 | 52.72 | 38.85 | 58.98 | 67.38 | 61.64 | 51.39 | 55.26 | 61.00 | 61.00 | 61.00 | 61.00 | 61.00 |
| 1.25 | 1.43 | 1.56 | 1.62 | 1.70 | 1.31 | 2.23 | 3.80 | 3.00 | 2.07 | 2.23 | 2.50 | 2.58 | 2.72 | 2.80 | 2.99 |
| 0.28 | 0.46 | 0.55 | 1.37 | -0.27 | 0.13 | 1.11 | 2.48 | 1.64 | 0.67 | 0.88 | 0.71 | 1.18 | 1.23 | 1.29 | 1.37 |
| 11.03 | 16.82 | 19.35 | 44.80 | -8.36 | 3.98 | 29.26 | 44.03 | 33.73 | 16.58 | 21.89 | 17.41 | 27.74 | 27.65 | 27.97 | 27.96 |
| 0.02 | 0.13 | 0.33 | 0.76 | -0.11 | -0.04 | 1.12 | 1.87 | 1.30 | 0.46 | 0.79 | 0.57 | 1.01 | 0.86 | 1.18 | 1.31 |
| -101.45 | 670.59 | 151.91 | 128.79 | -114.70 | -63.96 | -2,887.50 | 67.80 | -30.41 | -64.98 | 73.03 | -28.39 | 79.47 | -15.29 | 37.02 | 11.13 |
| 283.18 | 291.97 | 284.22 | 280.80 | 272.37 | 269.72 | 261.79 | 256.07 | 249.28 | 240.21 | 232.11 | 225.88 | 225.88 | 225.88 | 225.88 | 225.88 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Hologic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hologic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hologic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Hologic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hologic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Hologic stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic business model & stock analysis
Hologic SWOT Analysis
Strengths
Hologic Inc has several strengths that contribute to its success in the market. These strengths include:
- Strong brand reputation and recognition in the healthcare industry
- Wide range of innovative and high-quality medical devices and diagnostic solutions
- Strong financial performance and revenue growth
- Strong distribution network and global presence
- Commitment to research and development, leading to continuous product advancements
Weaknesses
Hologic Inc also has weaknesses that pose some challenges to the company. These weaknesses include:
- Relatively high production costs leading to higher product prices
- Dependence on a limited number of key suppliers for crucial components
- Limited diversification in terms of product portfolio
- Risk of regulatory changes affecting the healthcare industry
Opportunities
Despite the weaknesses, there are also opportunities for Hologic Inc to capitalize on. These opportunities include:
- Increased demand for advanced medical devices and diagnostic solutions
- Expansion into emerging markets with a growing healthcare sector
- Partnerships or acquisitions to enhance product portfolio diversification
- Technological advancements in the healthcare industry opening new possibilities
Threats
Hologic Inc faces certain threats that could negatively impact its business. These threats include:
- Intense competition from other major players in the medical device industry
- Changing regulatory environment and potential legal hurdles
- Economic downturn and reduced healthcare spending
- Emergence of substitute products or technologies
Hologic Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic Segments
Hologic Revenue by Segment (1/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (2/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (3/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (4/7)
3 Years
5 Years
Max
Details
Hologic Revenue by Segment (5/7)
3 Years
5 Years
10 Years
Max
Details
Hologic Revenue by Segment (6/7)
3 Years
5 Years
10 Years
Max
Details
Hologic Revenue by Segment (7/7)
3 Years
5 Years
10 Years
Max
Details
Hologic Revenue by Region
3 Years
5 Years
Max
Details
Hologic Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Hologic historical P/E ratio, EBIT multiple, and P/S ratio
Hologic annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Hologic shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Hologic stock splits
Current Hologic forecasts and price targets in September 2026
Analyst Price Targets 2026Hologic Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 1/12/2026 | Downgrade | BuyHold | – | |
| 1/5/2026 | Downgrade | OutperformIn Line | 62 | |
| 11/11/2025 | Maintained | Equal Weight | 45 | |
| 10/23/2025 | Downgrade | OutperformNeutral | 31 | |
| 10/22/2025 | Downgrade | OverweightEqual Weight | 64 | |
| 10/22/2025 | Downgrade | OutperformMarket Perform | 63 | |
| 10/22/2025 | Downgrade | OverweightNeutral | 52 | |
| 10/21/2025 | Maintained | Hold | 58 | |
| 10/21/2025 | Maintained | Market Perform | – | |
| 10/21/2025 | Maintained | Neutral | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Hologic Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/28/2026 | 1.13USD | - | 1.07 BUSD | - | 2026 Q3 |
| 4/30/2026 | 1.08USD | - | 1.05 BUSD | - | 2026 Q2 |
| 2/4/2026 | 1.11USD | - | 1.09 BUSD | - | 2026 Q1 |
| 11/7/2024 | 1.03USD | - | 997.29 MUSD | - | 2024 Q4 |
| 4/29/2024 | 1.00USD | - | 1.02 BUSD | - | 2024 Q2 |
| 1/30/2024 | 0.96USD | - | 995.56 MUSD | - | 2024 Q1 |
| 7/25/2023 | 0.89USD | - | 971.85 MUSD | - | 2023 Q3 |
| 4/25/2023 | 0.84USD | - | 937.40 MUSD | - | 2023 Q2 |
| 1/31/2023 | 0.88USD | - | 980.84 MUSD | - | 2023 Q1 |
| 10/31/2022 | 0.64USD | - | 876.81 MUSD | - | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Hologic stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Hologic shareholder structure
| % | Name |
|---|---|
11.41821% | |
9.89592% | |
6.37330% | |
5.65080% | |
4.39020% | |
4.33956% |
Hologic Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
46.30% | SEC ↗ | |
12.20% | SEC ↗ | |
12.20% | SEC ↗ | |
10.94% | SEC ↗ | |
10.20% | SEC ↗ | |
9.20% | SEC ↗ | |
8.90% | SEC ↗ | |
8.70% | SEC ↗ | |
7.49% | SEC ↗ | |
7.20% | SEC ↗ |
Hologic Executives and Management Board
18 members · avg. age 58 · 44 % women
Mr. Stephen Macmillan (61)
Chairman of the Board, President, Chief Executive Officer · since 2013
15.93 M USD
Management
Mr. Essex Mitchell (46)
Chief Operating Officer
Ms. Karleen Oberton (56)
Chief Financial Officer · since 2018
Mr. Jan Verstreken (58)
Group President - International
Dr. Jennifer Schneiders (58)
President - Diagnostic Solutions
Mr. Mark Horvath (63)
Division President, Breast and Skeletal Health Solutions
Mr. Brandon Schnittker (42)
President - GYN Surgical Solutions
Board of Directors
Ms. Amy Mcbride-Wendell (65)
Lead Independent Director
Dr. Martin Madaus (66)
Independent Director
Mr. Charles Dockendorff (71)
Independent Director
Ms. Nanaz Mohtashami (48)
Independent Director
Dr. Ludwig Hantson (63)
Independent Director
Ms. Christiana Stamoulis (55)
Independent Director
Hologic Supply Chain
Hologic Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.37 | 0.09 | 0.69 | ||
| 2 | 0.40 | 0.54 | 0.68 | ||
| 3 | -0.09 | -0.35 | 0.50 | ||
| 4 | 0.10 | 0.35 | 0.46 | ||
| 5 | -0.05 | 0.08 | 0.44 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0 | -0.50 | — | ||
| 2 | Grifols, S.A. | -0.18 | — | — | |
| 3 | 9342-8530 Quebec | — | — | — | |
| 4 | -0.08 | -0.62 | — | ||
| 5 | Tecan Group Ltd. | — | — | — |
Frequently asked questions about Hologic
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Analysts currently set an average price target of 76.66 USD for the Hologic stock (median: 77.52 USD), implying +0.9 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Hologic stock: 0 recommend buying, 20 holding and 3 selling. For 2026, analysts expect Hologic to generate revenue of 4.24 B USD and earnings per share of 4.49 USD.
Converted at the current exchange rate, the Hologic share trades at 65.52 EUR (76.01 USD).
The Hologic share (HOLX) is listed on 9 stock exchanges, including: NASDAQ (HOLX), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), London (0J5Q.L), London (0J5Q.L), SIX (Zürich) (HO1.SW).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
The expected revenue of Hologic is 4.24 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hologic is 1.01 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hologic is currently 16.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hologic stock.
The price-to-sales ratio (P/S) of Hologic is currently 4.05. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hologic stock.
The Eulerpool Quality Score for Hologic is 1/10.
The ISIN of Hologic is US4364401012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Hologic is 879100. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Hologic is HOLX. The ticker symbol is used to trade Hologic shares on the stock exchange.
Hologic paid dividends every year for the past 0 years.
Hologic is assigned to the 'Health' sector.
The dividends of Hologic are distributed in USD.
Hologic stock
Hologic Peer Group
Hologic Ticker
Hologic FIGI
All fundamentals and in-depth analysis of Hologic
Our stock analysis for Hologic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hologic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.